Patent ID: 9155792
Filing Date: 2015-10-13
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A pharmaceutical composition comprising a RecA inhibitor, and at least one physiologically acceptable carrier or excipient, wherein the composition further comprises at least one antibiotic and wherein the RecA inhibitor interacts directly with the RecA protein and wherein the RecA inhibitor is selected from the group consisting of: amentoflavone, hinokiflavone, isorhamnetin, maclurin, quercetagetin, quercetin dehydrate, 3,7,4′-trihydroxyflavone, theaflavin or a compound of formula (I) or formula (II) or pharmaceutical acceptable salts thereof or combinations thereof, wherein the compound of formula (I) has the following structure: wherein: X is oxygen, sulfur, or N(R); n is 0 to 4; R each R each R Q is a valence bond or a bivalent, saturated or unsaturated, straight or branched C each R is independently hydrogen or an optionally substituted aliphatic group; R Ring A is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein the compound of formula (II) has the following structure: wherein: Cy L each R is independently hydrogen or an optionally substituted C Cy L Cy